Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Corticosteroids for the treatment of respiratory infection by Mycoplasma pneumoniae in children: A cost‐utility analysis

Buendía JA. and Patiño DG., (2023), Pediatric Pulmonology

Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019

Shin YH. et al, (2023), Allergy

Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis

Teper A. et al, (2023), Archivos Argentinos de Pediatria

Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.

Buendia JA. et al, (2023), Expert Rev Pharmacoecon Outcomes Res, 1 - 7

Effectiveness of high-dose vitamin D supplementation to reduce the incidence rate of repeat episodes of pneumonia in children: A systematic review.

Buendía JA. et al, (2023), Pediatr Pulmonol

Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.

Buendía JA. et al, (2023), Value Health Reg Issues, 36, 44 - 50

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.

GBD 2021 Diabetes Collaborators None., (2023), Lancet

Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.

Sánchez J. et al, (2023), J Allergy Clin Immunol Pract

Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis.

Buendía JA. et al, (2023), Pediatr Pulmonol, 58, 1562 - 1568

Cost utility of vitamin D supplementation in adults with mild to moderate asthma.

Antonio Buendía J. et al, (2023), J Asthma, 60, 951 - 959

Cost-Utility of Continuous Positive Airway Pressure for Respiratory Distress in Preterm Infants in a Middle-Income Country.

Buendía JA. et al, (2023), Value Health Reg Issues, 35, 1 - 7

Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019.

GBD 2019 Chronic Respiratory Diseases Collaborators None., (2023), EClinicalMedicine, 59

Tiotropium for children and adolescents with severe asthma.

Antonio Buendía J. and Patiño DG., (2023), J Asthma, 60, 1009 - 1015

Cost-utility of vitamin D supplementation to prevent acute respiratory infections in children.

Buendía JA. and Patiño DG., (2023), Cost Eff Resour Alloc, 21

Comparison of three alternatives for the management of moderate asthma in children aged 6-11 years: a cost-utility analysis.

Antonio Buendía J. et al, (2023), J Asthma, 60, 761 - 768

Vitamin D supplementation for children with mild to moderate asthma: an economic evaluation.

Antonio Buendía J. et al, (2023), J Asthma, 1 - 9

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026.

Global Burden of Disease 2021 Health Financing Collaborator Network None., (2023), Lancet Glob Health, 11, e385 - e413

Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.

Castaldelli-Maia JM. et al, (2023), Lancet Psychiatry, 10, 85 - 97

Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis.

Antonio Buendía J. and Patiño DG., (2023), J Asthma, 60, 377 - 384

The role of high carbohydrate-rich food intake and severity of asthma exacerbation in children between 2 to 6 years aged.

Antonio Buendía J. et al, (2023), J Asthma, 60, 412 - 418

Load More

1
2
3
4
5
6
7

Include forthcoming?